Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer

NCT03144856 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT03144856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03144856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Unknown status
Start date
February 22, 2017
Completion date
March 1, 2019
Enrollment
39 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer